

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A method of treating a subject having an inflammatory condition, comprising administering to the subject a combination of an effective amount of methotrexate (MTX) and an effective amount of an agonist of the A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR agonist).

2. (Original) A method according to Claim 1, wherein MTX is administered to the subject once weekly.

3. (Currently Amended) A method according to Claim 1 ~~or 2~~, wherein the A<sub>3</sub>AR agonist is administered to subjects between once and a few times a day.

4. (Currently Amended) A method according to ~~any one of Claim 1 to 3~~ Claim 1, wherein the A<sub>3</sub>AR agonist is given to the subject orally.

5. (Currently Amended) A method according to ~~any one~~

~~of Claims 1 to 4~~ Claim 1, wherein the A<sub>3</sub>AR agonist is IB-MECA or Cl-IB-MECA.

6. (Currently Amended) A method according to ~~any one of Claims 3 to 6~~ Claim 3, wherein a daily dosage of said A<sub>3</sub>AR agonist is less than 4 mg.

7. (Original) A method according to Claim 6, wherein a daily dosage of said A<sub>3</sub>AR agonist is within the range of about 0.01 to about 2 mg.

8. (Original) A method according to Claim 7, wherein a daily dosage of said A<sub>3</sub>AR agonist is within the range of about 0.1 to about 1.5 mg.

9. (Currently Amended) A method according to ~~any one of Claims 1 to 8~~ Claim 1, wherein the inflammatory condition is an autoimmune disorder.

10. (Original) A method according to Claim 10, wherein said autoimmune disorder is rheumatoid arthritis.

11. (Original) The method according to Claim 10, wherein said A<sub>3</sub>AR agonist is IB-MECA.

12. (Original) A method of treating a subject having an inflammatory condition and treated with MTX, comprising administering to the subject an effective amount of an A<sub>3</sub>AR agonist.

13. (Original) A method of treating a subject having an inflammatory condition and indicated for treatment with an A<sub>3</sub>AR agonist, comprising administering to the subject an effective amount of MTX.

14. (Currently Amended) A method according to Claim ~~12 or 13~~, wherein the A<sub>3</sub>AR agonist is administered to the subject between once and a few times a day.

15. (Currently Amended) A method according to ~~any one of Claims 12 to 14~~ Claim 12, wherein the A<sub>3</sub>AR agonist is given to the subject orally.

16. (Currently Amended) A method according to ~~any one of Claims 12 to 15~~ Claim 12, wherein the A<sub>3</sub>AR agonist is IB-MECA or Cl-IB-MECA.

17. (Currently Amended) A method according to ~~any~~

~~one of Claims 12 to 16~~ Claim 12, wherein a daily dosage of said A<sub>3</sub>AR agonist is less than 4 mg.

18. (Original) A method according to Claim 17, wherein a daily dosage of said A<sub>3</sub>AR agonist is within the range of about 0.01 to about 2 mg.

19. (Original) A method according to Claim 18, wherein a daily dosage of said A<sub>3</sub>AR agonist is within the range of about 0.1 to about 1.5 mg.

20. (Currently Amended) A method according to ~~any~~ ~~one of Claims 12 to 19~~ Claim 12, wherein the inflammatory condition is an autoimmune disorder.

21. (Original) A method according to Claim 20, wherein said autoimmune disorder is rheumatoid arthritis.

Claims 22-36 (Cancelled).